Themed "Towards Clinical, Achieving Industry," this event features one main forum and four themed forums, promoting the development of cell drug products and accelerating the industrialization of cell pharmaceuticals from multiple perspectives including technological innovation, supply chain, clinical research, regulatory approval, and capital support.
May 13,According to an internal email from Novartis,Ingrid Zhang (Zhang Ying), currently President of the China region, will be appointed as Chief Commercial Officer (CCO).Based in Basel, Switzerland, leading the commercial launch strategy headquartered in Basel.（CLS）Team.
Zhang Ying joined Novartis in 2011.In April 2022, Novartis underwent a global organizational restructuring, merging its pharmaceuticals and oncology divisions into a single Innovative Medicines segment. In the same year, Novartis(China)And Novartis Oncology(China)Also merged into one.- On April 22, 2022, Novartis announced that Zhang Ying, then President of Novartis Pharmaceuticals (China), was appointed as the President and Managing Director of Innovative Medicines China.
- In September 2023, Dan Brindle (贝德年), then President of Novartis Group China, left his position.
- Starting from October 1, 2023, Zhang Ying (Ingrid), President of Novartis Innovative Drugs China, will take on the additional role of President of Novartis Group China.
Novartis stated in the email that under Zhang Ying's leadership,In Q1 2024, Novartis China delivered its first $1 billion quarterly performance, with a year-on-year increase of 25% (+31% cc).She brings strong business strategic capabilities and deep national experience — first in Poland, and now in China, one of Novartis' top markets, where her robust leadership has proven to be invaluable.Leo Lee will be appointed as General Manager of China, based in China, effective June 1.Leo Lee
Since 2020, Leo has been leading Novartis in Japan and driving the business back to growth.Novartis stated in the email that Leo's strong focus on commercial execution and compassionate leadership will become powerful assets, and they look forward to him elevating Novartis' business in China to a new level in the future.In addition, Keizo Miyazawa will serve as the interim General Manager for Japan during the transition period.[Reprint Statement] This article is reprinted from the "MedTalent Medical Talent" WeChat Official Account.
For more high-quality content, please follow.↓↓↓
